A Phase 2 interventional study of oral treprostinil in PAH, sponsored by United Therapeutics. Completed at 9 sites in United States. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2) transitioning from inhaled prostacyclin therapy; or (3) not currently receiving prostacyclin therapy.
Study TDE-PH-206 was a multicenter, open-label study designed to investigate the safety, tolerability, and PK of oral treprostinil administered 3 times daily (TID) or 4 times daily (QID), at the discretion of the Investigator, with food in pediatric PAH subjects aged 7 to 17 years of age (1) transitioning from continuous IV/SC Remodulin, (2) transitioning from inhaled prostacyclin, or (3) as add-on to current PAH therapies in de novo prostacyclin subjects. Eligible subjects were assigned to a cohort based upon their background therapy. All subjects received oral treprostinil provided as 0.125, 0.25, 1, or 2.5 mg extended-release tablets. Subjects in Cohort 1 began the transition from IV/SC Remodulin in the hospital with a goal of complete transition to oral treprostinil within 5 days. The initial dose of oral treprostinil for Cohort 1 was calculated from the subject's dose of IV/SC Remodulin and weight. Subjects in Cohorts 2 and 3 were initiated on 0.125 mg TID or QID oral treprostinil with dose escalations possible every 24 hours in increments of 0.125 mg TID or QID at the discretion of the Investigator during the first 4 weeks, and in increments of either 0.125 mg or 0.25 mg every 24 hours thereafter. Cross titration occurred for Cohorts 1 and 2 such that doses of IV/SC Remodulin or inhaled prostacyclin were decreased as subjects were fully transitioned to oral treprostinil.
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject had a current diagnosis of PAH (WHO Group I) associated with:
The subject had a current diagnosis of PAH confirmed by RHC prior to the Screening Visit with the following parameters:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transitioned from IV or SC Remodulin to oral treprostinil
Drug: oral treprostinil
Transitioned from inhaled prostacyclin to oral treprostinil
Drug: oral treprostinil
Treated with oral treprostinil as a de novo add-on to current PAH therapy
Drug: oral treprostinil
Also known as: Orenitram
Number of Participants With Successful Transition From IV/SC Remodulin to Oral Treprostinil (Cohort 1), From Inhaled Prostacyclin to Oral Treprostinil (Cohort 2), or as an add-on to Current PAH Therapy in de Novo Prostacyclin Subjects (Cohort 3).
A successful transition was defined as a subject from Cohort 1 or Cohort 2 who was receiving oral treprostinil and no longer receiving IV/SC Remodulin or inhaled prostacyclin, respectively, at Week 4 and clinically maintained on oral treprostinil treatment through Week 24. A successful initiation of oral treprostinil for Cohort 3 was defined as a subject who was clinically maintained on oral treprostinil through Week 24.
Time frame: Up to 24 weeks
Cardiopulmonary Exercise Testing - Change From Baseline in Peak Oxygen Uptake (VO2) at Week 24
Cardiopulmonary Exercise Testing (CPET) was performed with progressive cycle ergometry and ventilatory expired gas analysis obtained using a metabolic cart at Baseline and Week 24/Premature Termination. CPET consisted of measuring oxygen uptake (VO2), carbon dioxide output (VCO2), minute ventilation (VE), and other variables in addition to a 12-lead ECG, blood pressure (BP) monitoring, and pulse oximetry.
Time frame: Baseline and Week 24
Cardiopulmonary Exercise Testing - Change From Baseline in Minute Ventilation (VE)/Carbon Dioxide Output (VCO2) Slope at Week 24
Cardiopulmonary Exercise Testing (CPET) was performed with progressive cycle ergometry and ventilatory expired gas analysis obtained using a metabolic cart at Baseline and Week 24/Premature Termination. CPET consisted of measuring oxygen uptake (VO2), carbon dioxide output (VCO2), minute ventilation (VE), and other variables in addition to a 12-lead ECG, blood pressure (BP) monitoring, and pulse oximetry.
Time frame: Baseline and Week 24
Cardiopulmonary Exercise Testing - Change From Baseline in Peak Watts at Week 24
Cardiopulmonary Exercise Testing (CPET) was performed with progressive cycle ergometry and ventilatory expired gas analysis obtained using a metabolic cart at Baseline and Week 24/Premature Termination. CPET consisted of measuring oxygen uptake (VO2), carbon dioxide output (VCO2), minute ventilation (VE), and other variables in addition to a 12-lead ECG, blood pressure (BP) monitoring, and pulse oximetry.
Time frame: Baseline and Week 24
Change in Symptoms of PAH From Baseline to Week 24
PAH symptoms (fatigue, dyspnea, edema, dizziness, syncope, chest pain, orthopnea) were assessed at the Baseline Visit prior to the initiation of oral treprostinil dosing and at Week 24. Scores range from 0 (for the best condition) to 3 (for the worst condition).
Time frame: Baseline and Week 24
Change in Panama Functional Class From Baseline to Week 24
Change from Baseline in subject clinical status was recorded according to the Panama Functional Class.
Time frame: Baseline and Week 24
Change in WHO Functional Class From Baseline to Week 24
Change from Baseline in subject clinical status was recorded according to the WHO Functional Class.
Time frame: Baseline and Week 24
Change in 6-Minute Walk Distance (6MWD) From Baseline to Week 24
The intent of the 6MWT was to evaluate exercise capacity associated with carrying out activities of daily living. Total distance covered in a total of 6 minutes was measured. Oxygen saturation and heart rate (HR) were measured at rest prior to the 6MWT and monitored continuously during the walk. Recovery monitoring (HR and oxygen saturation) was performed and documented at Minute 0 (immediately upon stopping the 6MWT), Minute 1, Minute 2, and Minute 3 post walk.
Time frame: Baseline and Week 24
Change in Borg Dyspnea Score From Baseline to Week 24
The Borg dyspnea score was assessed prior to and following the completion of the 6MWT at Week 24. The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) to 10 (for the worst condition).
Time frame: Baseline and Week 24
Change in Quality of Life Assessed Via the Pediatric Quality of Life Inventory (PedsQL) Questionnaire From Baseline to Week 24
Four subscales \[items\]: (Physical \[8\], Emotional \[5\], Social \[5\], School Functioning \[5\]). Subjects and subjects' parent(s) completed PedsQL at Week 24. Response to each item on the subscales were graded 0-4 (0=never a problem, 1=almost never a problem, 2=sometimes a problem, 3=often a problem, 4=almost always a problem). Response to each item was transformed from the 0-4 scale to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Using transformed values, mean was computed as sum of the items in each subscale over number of items answered in the same subscale. Two summary scores (Psychosocial Health Summary Score and Total Scale Score) were calculated with a range of 0-100 (higher values indicating better outcome). Psychosocial Health Summary Score was mean computed as sum of the items over the number of items answered in the Emotional, Social, and School Functioning Scales. Total Score was calculated as sum of all items over number of items answered on all the scales.
Time frame: Baseline and Week 24
Change in Plasma N-terminal Pro-B-type Natriuretic Peptide (NT-Pro BNP) From Baseline to Week 24
Plasma NT-proBNP concentration is a useful biomarker for PAH as it is associated with changes in right heart morphology and function.
Time frame: Baseline and Week 24
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
Time frame: Baseline and Week 24
Change From Baseline in Left Ventricular (LV) Stroke Volume Index at Week 24
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
Time frame: Baseline and Week 24
Change From Baseline in Right Ventricular (RV) Cardiac Output Index at Week 24
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
Time frame: Baseline and Week 24
Change From Baseline in Right Ventricular End-diastolic Volume (RVEDV) Index at Week 24
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
Time frame: Baseline and Week 24
Change From Baseline in Right Ventricular Ejection Fraction (RVEF) at Week 24
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
Time frame: Baseline and Week 24
Change From Baseline in Right Ventricular End-systolic Volume (RVESV) Index at Week 24
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
Time frame: Baseline and Week 24
Change From Baseline in Right Ventricular (RV) Mass Index at Week 24
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
Time frame: Baseline and Week 24
Change From Baseline in Right Ventricular (RV) Stroke Volume Index at Week 24
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
Time frame: Baseline and Week 24
Maximum Observed Drug Concentration in Plasma (Cmax)
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able. For the purposes of PK analysis, data for Cohorts 1, 2, and 3 following oral treprostinil administration were combined and compared to parenteral infusion (Cohort 1 Baseline data; Remodulin IV/SC).
Time frame: Baseline (Cohort 1 only; 0, 4, 8 hours while receiving IV/SC Remodulin) and Week 24 (all cohorts; 0, 2, 4, 6, 8 hours post-dose oral treprostinil)
Last Observed Drug Concentration in Plasma (Clast)
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
Time frame: Baseline (Cohort 1 only; 0, 4, 8 hours while receiving IV/SC Remodulin) and Week 24 (all cohorts; 0, 2, 4, 6, 8 hours post-dose oral treprostinil)
Average Drug Concentration in Plasma (Cavg)
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
Time frame: Baseline (Cohort 1 only; 0, 4, 8 hours while receiving IV/SC Remodulin) and Week 24 (all cohorts; 0, 2, 4, 6, 8 hours post-dose oral treprostinil)
Observed Minimum Drug Concentration in Plasma (Cmin)
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
Time frame: Baseline (Cohort 1 only; 0, 4, 8 hours while receiving IV/SC Remodulin) and Week 24 (all cohorts; 0, 2, 4, 6, 8 hours post-dose oral treprostinil)
Area Under the Concentration-Time Curve From Zero to Tau Hours Post-dose (AUCtau)
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
Time frame: Baseline (Cohort 1 only; 0, 4, 8 hours while receiving IV/SC Remodulin) and Week 24 (all cohorts; 0, 2, 4, 6, 8 hours post-dose oral treprostinil)
Area Under the Concentration-Time Curve From Zero to 8 Hours Post-dose (AUC0-8)
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
Time frame: Baseline (Cohort 1 only; 0, 4, 8 hours while receiving IV/SC Remodulin) and Week 24 (all cohorts; 0, 2, 4, 6, 8 hours post-dose oral treprostinil)
| Milestone | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Started | 10 | 10 | 12 |
| Completed | 9 | 10 | 12 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
A successful transition was defined as a subject from Cohort 1 or Cohort 2 who was receiving oral treprostinil and no longer receiving IV/SC Remodulin or inhaled prostacyclin, respectively, at Week 4 and clinically maintained on oral treprostinil treatment through Week 24. A successful initiation of oral treprostinil for Cohort 3 was defined as a subject who was clinically maintained on oral treprostinil through Week 24.
| participants | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Successfully transitioned/initiated within 4 weeks | 10 | 10 | 12 |
| Successfully maintained through 24 weeks | 9 | 10 | 12 |
Cardiopulmonary Exercise Testing (CPET) was performed with progressive cycle ergometry and ventilatory expired gas analysis obtained using a metabolic cart at Baseline and Week 24/Premature Termination. CPET consisted of measuring oxygen uptake (VO2), carbon dioxide output (VCO2), minute ventilation (VE), and other variables in addition to a 12-lead ECG, blood pressure (BP) monitoring, and pulse oximetry.
| mL/kg/min | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Cardiopulmonary Exercise Testing - Change From Baseline in Peak Oxygen Uptake (VO2) at Week 24 | -3.26 ± 7.34 | 2.18 ± 8.01 | 2.00 ± 3.47 |
Cardiopulmonary Exercise Testing (CPET) was performed with progressive cycle ergometry and ventilatory expired gas analysis obtained using a metabolic cart at Baseline and Week 24/Premature Termination. CPET consisted of measuring oxygen uptake (VO2), carbon dioxide output (VCO2), minute ventilation (VE), and other variables in addition to a 12-lead ECG, blood pressure (BP) monitoring, and pulse oximetry.
| VE/VCO2 Slope | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Cardiopulmonary Exercise Testing - Change From Baseline in Minute Ventilation (VE)/Carbon Dioxide Output (VCO2) Slope at Week 24 | -1.066 ± 3.169 | 2.170 ± 5.111 | 1.531 ± 3.821 |
Cardiopulmonary Exercise Testing (CPET) was performed with progressive cycle ergometry and ventilatory expired gas analysis obtained using a metabolic cart at Baseline and Week 24/Premature Termination. CPET consisted of measuring oxygen uptake (VO2), carbon dioxide output (VCO2), minute ventilation (VE), and other variables in addition to a 12-lead ECG, blood pressure (BP) monitoring, and pulse oximetry.
| Watts | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Cardiopulmonary Exercise Testing - Change From Baseline in Peak Watts at Week 24 | 4.8 ± 10.3 | -2.8 ± 11.9 | 6.5 ± 12.9 |
PAH symptoms (fatigue, dyspnea, edema, dizziness, syncope, chest pain, orthopnea) were assessed at the Baseline Visit prior to the initiation of oral treprostinil dosing and at Week 24. Scores range from 0 (for the best condition) to 3 (for the worst condition).
| Participants | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Chest Pain - Improved - Week 24 | 0 | 0 | 2 |
| Chest Pain - No Change - Week 24 | 8 | 9 | 8 |
| Chest Pain - Deteriorated - Week 24 | 1 | 1 | 2 |
| Dizziness - Improved - Week 24 | 0 | 0 | 4 |
| Dizziness - No Change - Week 24 | 9 | 8 | 8 |
| Dizziness - Deteriorated - Week 24 | 0 | 2 | 0 |
| Dyspnea - Improved - Week 24 | 3 | 0 | 5 |
| Dyspnea - No Change - Week 24 | 4 | 8 | 6 |
| Dyspnea - Deteriorated - Week 24 | 2 | 2 | 1 |
| Edema - Improved - Week 24 | 0 | 0 | 1 |
| Edema - No Change - Week 24 | 8 | 10 | 10 |
| Edema - Deteriorated - Week 24 | 1 | 0 | 1 |
| Fatigue - Improved - Week 24 | 0 | 3 | 2 |
| Fatigue - No Change - Week 24 | 5 | 6 | 9 |
| Fatigue - Deteriorated - Week 24 | 4 | 1 | 1 |
| Orthopnea - Improved - Week 24 | 0 | 0 | 3 |
| Orthopnea - No Change - Week 24 | 9 | 10 | 9 |
| Orthopnea - Deteriorated - Week 24 | 0 | 0 | 0 |
Change from Baseline in subject clinical status was recorded according to the Panama Functional Class.
| Participants | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Improved - Week 24 | 0 | 2 | 3 |
| No Change - Week 24 | 9 | 7 | 9 |
| Deteriorated - Week 24 | 0 | 1 | 0 |
Change from Baseline in subject clinical status was recorded according to the WHO Functional Class.
| Participants | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Improved - Week 24 | 0 | 1 | 3 |
| No Change - Week 24 | 9 | 8 | 9 |
| Deteriorated - Week 24 | 0 | 1 | 0 |
The intent of the 6MWT was to evaluate exercise capacity associated with carrying out activities of daily living. Total distance covered in a total of 6 minutes was measured. Oxygen saturation and heart rate (HR) were measured at rest prior to the 6MWT and monitored continuously during the walk. Recovery monitoring (HR and oxygen saturation) was performed and documented at Minute 0 (immediately upon stopping the 6MWT), Minute 1, Minute 2, and Minute 3 post walk.
| meters | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change in 6-Minute Walk Distance (6MWD) From Baseline to Week 24 | 2.7 ± 94.2 | 22.1 ± 86.5 | 12.8 ± 49.6 |
The Borg dyspnea score was assessed prior to and following the completion of the 6MWT at Week 24. The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) to 10 (for the worst condition).
| score on a scale | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change in Borg Dyspnea Score From Baseline to Week 24 | -1.56 ± 3.51 | 0.05 ± 1.50 | -0.83 ± 1.59 |
Four subscales \[items\]: (Physical \[8\], Emotional \[5\], Social \[5\], School Functioning \[5\]). Subjects and subjects' parent(s) completed PedsQL at Week 24. Response to each item on the subscales were graded 0-4 (0=never a problem, 1=almost never a problem, 2=sometimes a problem, 3=often a problem, 4=almost always a problem). Response to each item was transformed from the 0-4 scale to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Using transformed values, mean was computed as sum of the items in each subscale over number of items answered in the same subscale. Two summary scores (Psychosocial Health Summary Score and Total Scale Score) were calculated with a range of 0-100 (higher values indicating better outcome). Psychosocial Health Summary Score was mean computed as sum of the items over the number of items answered in the Emotional, Social, and School Functioning Scales. Total Score was calculated as sum of all items over number of items answered on all the scales.
| score on a scale | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Physical Functioning - Child - Week 24 | 5.57 ± 22.14 | -2.82 ± 11.09 | 5.48 ± 13.40 |
| Emotional Functioning - Child - Week 24 | 8.33 ± 11.46 | 3.00 ± 13.98 | 2.92 ± 13.05 |
| Social Functioning - Child - Week 24 | 9.44 ± 16.85 | 0.00 ± 15.09 | 1.25 ± 11.31 |
| School Functioning - Child - Week 24 | 3.89 ± 23.29 | -6.50 ± 11.56 | 7.92 ± 21.37 |
| Psychosocial Health - Child - Week 24 | 7.23 ± 13.52 | -1.17 ± 11.11 | 4.04 ± 11.85 |
| Total Scale Score - Child - Week 24 | 6.64 ± 15.08 | -1.76 ± 8.54 | 4.53 ± 11.46 |
| Physical Functioning - Parent - Week 24 | 1.72 ± 12.31 | -2.81 ± 14.98 | 1.29 ± 14.67 |
| Emotional Functioning - Parent - Week 24 | -2.22 ± 15.63 | 2.50 ± 10.07 | 5.00 ± 18.95 |
| Social Functioning - Parent - Week 24 | -1.11 ± 14.53 | -5.50 ± 18.92 | 11.67 ± 16.28 |
| School Functioning - Parent - Week 24 | 9.44 ± 16.85 | -5.50 ± 11.65 | 5.00 ± 13.14 |
| Psychosocial Health - Parent - Week 24 | 2.04 ± 13.80 | -2.81 ± 11.48 | 7.22 ± 13.21 |
| Total Scale Score - Parent - Week 24 | 1.93 ± 11.79 | -2.84 ± 12.29 | 5.17 ± 12.78 |
Plasma NT-proBNP concentration is a useful biomarker for PAH as it is associated with changes in right heart morphology and function.
| pg/mL | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change in Plasma N-terminal Pro-B-type Natriuretic Peptide (NT-Pro BNP) From Baseline to Week 24 | 87.156 ± 281.664 | 81.930 ± 245.534 | 160.617 ± 549.953 |
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
| percentage of LVEF | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24 | -1.0 ± 1.4 | 2.4 ± 6.0 | -2.4 ± 3.1 |
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
| mL/beat/m2 | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change From Baseline in Left Ventricular (LV) Stroke Volume Index at Week 24 | -4.003 ± 2.688 | 6.336 ± 8.448 | 1.113 ± 5.539 |
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
| L/min/m2 | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change From Baseline in Right Ventricular (RV) Cardiac Output Index at Week 24 | 0.303 ± 0.209 | 0.767 ± 1.010 | 0.121 ± 1.047 |
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
| mL/m^2 | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change From Baseline in Right Ventricular End-diastolic Volume (RVEDV) Index at Week 24 | -8.190 ± 12.887 | 12.131 ± 14.382 | 10.601 ± 26.115 |
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
| percentage of RVEF | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change From Baseline in Right Ventricular Ejection Fraction (RVEF) at Week 24 | 4.0 ± 7.6 | 0.4 ± 7.1 | -0.7 ± 2.7 |
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
| mL/m2 | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change From Baseline in Right Ventricular End-systolic Volume (RVESV) Index at Week 24 | -7.975 ± 12.614 | 5.884 ± 12.965 | 5.722 ± 13.807 |
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
| g/m2 | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change From Baseline in Right Ventricular (RV) Mass Index at Week 24 | 2.375 ± 6.226 | 3.041 ± 7.890 | 0.614 ± 3.450 |
Cardiac MRI imaging was performed in all subjects aged 10 years and older at Baseline and Week 24/Premature Termination; imaging was optionally performed in subjects under the age of 10 years. The subject's BP was taken immediately prior to the cMRI assessment in the supine position to measure vascular parameters.
| mL/beat//m2 | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| Change From Baseline in Right Ventricular (RV) Stroke Volume Index at Week 24 | -0.215 ± 1.557 | 6.193 ± 8.015 | 1.458 ± 6.719 |
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able. For the purposes of PK analysis, data for Cohorts 1, 2, and 3 following oral treprostinil administration were combined and compared to parenteral infusion (Cohort 1 Baseline data; Remodulin IV/SC).
| ng/mL | Cohort 1 (Transitioning From Parenteral) | Cohorts Combined After Oral Treprostinil Administration |
|---|---|---|
| Maximum Observed Drug Concentration in Plasma (Cmax) | 5.14 ± 39.4 | 4.91 ± 50.5 |
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
| ng/mL | Cohort 1 (Transitioning From Parenteral) | Cohorts Combined After Oral Treprostinil Administration |
|---|---|---|
| Last Observed Drug Concentration in Plasma (Clast) | 4.66 ± 38.6 | 0.985 ± 104 |
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
| ng/mL | Cohort 1 (Transitioning From Parenteral) | Cohorts Combined After Oral Treprostinil Administration |
|---|---|---|
| Average Drug Concentration in Plasma (Cavg) | 4.28 ± 37.7 | 2.80 ± 54.5 |
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
| ng/mL | Cohort 1 (Transitioning From Parenteral) | Cohorts Combined After Oral Treprostinil Administration |
|---|---|---|
| Observed Minimum Drug Concentration in Plasma (Cmin) | 3.45 ± 47.9 | 0.799 ± 88.5 |
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
| h*ng/mL | Cohort 1 (Transitioning From Parenteral) | Cohorts Combined After Oral Treprostinil Administration |
|---|---|---|
| Area Under the Concentration-Time Curve From Zero to Tau Hours Post-dose (AUCtau) | 34.3 ± 37.7 | 22.2 ± 53.8 |
Cohort 1 had three blood samples obtained at 'Time 0' and at 4 and 8 hours at the Baseline visit. All cohorts had five blood samples obtained from at 'Time 0' and at 2, 4, 6, and 8 hours at the Week 24 visit. Plasma samples were analyzed for treprostinil using a validated bioanalytical plasma assay. Individual and mean treprostinil plasma concentration data and treprostinil pharmacokinetic parameters, such as peak observed plasma concentration (Cmax), time to peak plasma concentration (Tmax), area under the plasma concentration-time curve (AUC0-inf), were determined as able.
| h*ng/mL | Cohort 1 (Transitioning From Parenteral) | Cohorts Combined After Oral Treprostinil Administration |
|---|---|---|
| Area Under the Concentration-Time Curve From Zero to 8 Hours Post-dose (AUC0-8) | 34.3 ± 37.7 | 22.4 ± 54.3 |
Collected over Adverse events were recorded from the time that each subject and/or caregiver signed the ICF until the time screen failure was documented, or until the subject was either discontinued from the study or all Week 24 study assessments were completed.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (Transitioning From Parental) | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Cohort 2 (Transitioning From Inhaled) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Cohort 3 (Add-on to Current PAH Therapy) | 0/12 (0%) | 4/12 (33.3%) | 12/12 (100%) |
| Event | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| SeizureNervous system disorders | 2/10 | 0/10 | 0/12 |
| Chest painGeneral disorders | 0/10 | 0/10 | 2/12 |
| Device related infectionInfections and infestations | 1/10 | 0/10 | 0/12 |
| Stoma site infectionInfections and infestations | 1/10 | 0/10 | 0/12 |
| SyncopeNervous system disorders | 1/10 | 0/10 | 0/12 |
| TachycardiaCardiac disorders | 0/10 | 0/10 | 1/12 |
| PneumoniaInfections and infestations | 0/10 | 0/10 | 1/12 |
| Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders | 0/10 | 0/10 | 1/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/10 | 0/10 | 1/12 |
| Event | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) |
|---|---|---|---|
| HeadacheNervous system disorders | 6/10 | 8/10 | 12/12 |
| VomitingGastrointestinal disorders | 9/10 | 5/10 | 7/12 |
| DiarrhoeaGastrointestinal disorders | 6/10 | 7/10 | 9/12 |
| NauseaGastrointestinal disorders | 7/10 | 5/10 | 9/12 |
| FlushingVascular disorders | 6/10 | 4/10 | 8/12 |
| Pain in jawMusculoskeletal and connective tissue disorders | 1/10 | 1/10 | 6/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/10 | 5/10 | 2/12 |
| Abdominal pain upperGastrointestinal disorders | 4/10 | 4/10 | 5/12 |
| Chest painGeneral disorders | 1/10 | 0/10 | 5/12 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/10 | 1/10 | 5/12 |
| Age, Categorical(Participants) | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) | Total |
|---|---|---|---|---|
| <=18 years | 10 | 10 | 12 | 32 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) | Total |
|---|---|---|---|---|
| Median | 10.0 (7 to 17) | 13.5 (8 to 17) | 13.5 (8 to 17) | 12 (7 to 17) |
| Sex: Female, Male(Participants) | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) | Total |
|---|---|---|---|---|
| Female | 9 | 7 | 7 | 23 |
| Male | 1 | 3 | 5 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 1 | 7 |
| Not Hispanic or Latino | 6 | 8 | 11 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 1 | 1 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 7 | 9 | 10 | 26 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Cohort 1 (Transitioning From Parental) | Cohort 2 (Transitioning From Inhaled) | Cohort 3 (Add-on to Current PAH Therapy) | Total |
|---|---|---|---|---|
| United States | 10 | 10 | 12 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2014 to primary completion in Jul 2017, 31 months.
Results were first posted in Jan 2019, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil